Black Diamond Therapeutics Inc
Research Black Diamond Therapeutics Inc (BDTX) on Bullrun: market cap USD 105.13M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBDTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 105.13M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 9.91M
- Free cash flow-USD 7.97M
Valuation Snapshot
latest market cap is USD 105.13M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 70.00M | USD 22.37B | USD 29.61M | n/a | 0.39 | USD 20.99M | USD 18.78M | USD 112.21M |
| FY2024 | USD 0 | -USD 69.68B | -USD 62.30M | n/a | -1.27 | USD 36.44M | USD 22.19M | USD 83.29M |
| FY2023 | USD 0 | -USD 82.44M | -USD 66.75M | n/a | -1.88 | USD 56.22M | USD 25.30M | USD 116.74M |
| FY2022 | USD 0 | -USD 91.17M | -USD 85.27M | n/a | -2.52 | USD 34.32M | USD 28.14M | USD 115.70M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 105.13M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 138.85M | 6.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 121.22M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 145.09M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 65.46M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 193.13M | n/a | n/a | n/a |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Black Diamond Therapeutics Inc's market cap?
Black Diamond Therapeutics Inc's market capitalization is USD 105.13M.
What does Black Diamond Therapeutics Inc do?
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.